Immunoprecise Ebit from 2010 to 2024

IPA Stock  USD 1.26  0.02  1.56%   
Immunoprecise Antibodies' EBIT is decreasing over the years with slightly volatile fluctuation. Overall, EBIT is projected to go to about -23.9 M this year. From 2010 to 2024 Immunoprecise Antibodies EBIT quarterly data regression line had arithmetic mean of (7,819,726) and r-squared of  0.72. View All Fundamentals
 
EBIT  
First Reported
1997-01-31
Previous Quarter
-2.8 M
Current Value
-2.8 M
Quarterly Volatility
1.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.1 M, Interest Expense of 32.8 K or Total Revenue of 25 M, as well as many exotic indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.0043 or Days Sales Outstanding of 0.39. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules.
  
This module can also supplement Immunoprecise Antibodies' financial leverage analysis and stock options assessment as well as various Immunoprecise Antibodies Technical models . Check out the analysis of Immunoprecise Antibodies Correlation against competitors.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

Latest Immunoprecise Antibodies' Ebit Growth Pattern

Below is the plot of the Ebit of Immunoprecise Antibodies over the last few years. It is Immunoprecise Antibodies' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunoprecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
Ebit10 Years Trend
Slightly volatile
   Ebit   
       Timeline  

Immunoprecise Ebit Regression Statistics

Arithmetic Mean(7,819,726)
Geometric Mean1,722,646
Coefficient Of Variation(129.66)
Mean Deviation8,214,879
Median(3,894,000)
Standard Deviation10,139,233
Sample Variance102.8T
Range28.2M
R-Value(0.85)
Mean Square Error31.1T
R-Squared0.72
Significance0.000065
Slope(1,922,870)
Total Sum of Squares1439.3T

Immunoprecise Ebit History

2024-23.9 M
2023-25.2 M
2022-27.9 M
2021-15.9 M
2020-3.9 M
2019-3.8 M
2018-6.2 M

Other Fundumenentals of Immunoprecise Antibodies

About Immunoprecise Antibodies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunoprecise Antibodies income statement, its balance sheet, and the statement of cash flows. Immunoprecise Antibodies investors use historical funamental indicators, such as Immunoprecise Antibodies's Ebit, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may use each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunoprecise Antibodies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBIT-25.2 M-23.9 M
EBITDA-19.1 M-18.2 M
Ebt Per Ebit 1.67  2.48 
Ebit Per Revenue(0.02)(0.02)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:
Check out the analysis of Immunoprecise Antibodies Correlation against competitors.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Global Correlations
Find global opportunities by holding instruments from different markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.42)
Revenue Per Share
0.939
Quarterly Revenue Growth
0.203
Return On Assets
(0.11)
Return On Equity
(0.26)
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.